Merck & Co., Inc. (MRK)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 125.85 |
| Open | 127.24 |
| Bid | 125.03 x 800 |
| Ask | 125.59 x 800 |
| Day's Range | 125.05 - 128.70 |
| 52 Week Range | 99.14 - 134.63 |
| Volume | |
| Avg. Volume | 8,233,711 |
| Market Cap | 317.26B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 139.18 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.08 (2.46%) |
| Ex-Dividend Date | Sept 16, 2024 |
| 1y Target Est | N/A |
- Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
RAHWAY, N.J., July 26, 2024--Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Advanced Bladder Cancer
- Business Wire
Merck Announces Fourth-Quarter 2024 Dividend
RAHWAY, N.J., July 23, 2024--Merck Announces Fourth-Quarter 2024 Dividend
- Business Wire
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
RAHWAY, N.J., July 23, 2024--Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational RSV Preventative Monoclonal Antibody for Infants
© 2024 Yahoo. All rights reserved.